Merck & Co Maps Out Route To $10bn Cardiovascular Franchise
Eight Approvals Targeted By 2030
Executive Summary
The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.
You may also be interested in...
Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.
As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position
Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.
CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.